BPC-157 + TB-500

Overview

Pre-mixed blend of BPC-157 and TB-500 (a synthetic Thymosin β4 fragment) in a single vial, marketed for tissue repair. This blend is not clinically validated; the evidence base is inferred from individual component peptides, both of which are grey-market research compounds with no FDA-approved human indications and no controlled human efficacy trials.

Mechanism of Action

Mechanistic claims are extrapolated from preclinical (largely rodent) data on each component: BPC-157 has been reported to promote angiogenesis via VEGF/NO signaling, and TB-500 to promote actin polymerization and cell migration. Any additive or synergistic effect of the combination in humans has not been demonstrated in controlled trials.

Research Summary

No human efficacy trial has been published for this blend. The blend format is a vendor convenience (single reconstitution, single injection), not a clinically validated protocol. Component-level evidence is preclinical.

Vendors selling BPC-157 + TB-500

Scored vendors carrying BPC-157 + TB-500, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer BPC-157 + TB-500

120 prescribers in our directory work with BPC-157 + TB-500, each confirmed from their own website. Peptides like BPC-157 + TB-500 require a prescription from a licensed provider.

Reported Side Effects

• See individual compound profiles for BPC-157 and TB-500

Frequently asked questions

Has BPC-157 + TB-500 been independently lab-tested?

Disclosed Labs has collected 102 Certificates of Analysis (COA) for BPC-157 + TB-500 from 14 independent testing labs. 38 vendors have submitted material for testing. Products average 99.6% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/bpc-157-tb-500/testing.

What is the average purity of BPC-157 + TB-500 on the market?

Based on 102 COAs analyzed by Disclosed Labs, BPC-157 + TB-500 products average 99.6% (±0.3%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/bpc-157-tb-500/coas.

Which labs have tested BPC-157 + TB-500?

Independent labs that have tested BPC-157 + TB-500 include: ILS Labs (Grade A), Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source BPC-157 + TB-500?

8 vendors with Disclosed Labs trust grades currently list BPC-157 + TB-500, including Glacier Aminos, Ion Peptide, Voltera Sciences. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/bpc-157-tb-500.

Which prescribers offer BPC-157 + TB-500 with a prescription?

120 prescribers in the Disclosed Labs directory work with BPC-157 + TB-500, each confirmed from their own website. BPC-157 + TB-500 requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=BPC-157%20%2B%20TB-500.

How does BPC-157 + TB-500 work?

Mechanistic claims are extrapolated from preclinical (largely rodent) data on each component: BPC-157 has been reported to promote angiogenesis via VEGF/NO signaling, and TB-500 to promote actin polymerization and cell migration. Any additive or synergistic effect of the combination in humans has not been demonstrated in controlled trials.

What does the research say about BPC-157 + TB-500?

No human efficacy trial has been published for this blend. The blend format is a vendor convenience (single reconstitution, single injection), not a clinically validated protocol. Component-level evidence is preclinical.